Selected gene Combinations | Oncogenic signaling Pathway | Multivariate Cox model p-value | Univariate log-rank p-value | Survival probability | Number of subjects | HR [95% confidence intervals] |
---|---|---|---|---|---|---|
Low SOCS1 + High CDK1 | Cell cycle | 0.0152 | 0.0153 | Poor | 17 | 2.56 [1.28–5.11] |
Low SOCS1 + High CXCL8 | RTK signalling, angiogenesis | < 0.0001 | < 0.0001 | Poor | 4 | 7.97 [2.85–22.25] |
Low SOCS1 + High IGF1Ra | RTK signalling, angiogenesis | 0.0051 | 0.007 | Poor | 6 | 5.98 [2.09–17.13] |
Low SOCS1 + High CSF1 | Proliferation | 0.0042 | 0.0042 | Poor | 11 | 2.62 [1.19–5.78] |
Low SOCS1 + High DAB2 | MAPK pathway | < 0.0001 | < 0.0001 | Poor | 8 | 7.73 [3.45–17.35] |
Low SOCS1 + Low PIK3R1 | PI3K-AKT pathway | 0.0102 | 0.0102 | Poor | 9 | 3.52 [1.55–8.01] |
Low SOCS1 + High TSC1 | PI3K-AKT pathway | 0.0248 | 0.0274 | Poor | 24 | 2.84 [1.50–5.38] |
Low SOCS1 + High RAF1a | MAPK pathway | 0.0046 | 0.0291 | Better | 28 | 0.281 [0.11–0.71] |
Low SOCS1 + High AKT1S1 | PI3K-AKT pathway | 0.0034 | 0.0187 | Better | 15 | 0.08 [0.02–0.36] |
Low SOCS1 + Low PIK3R2b | PI3K-AKT pathway | 0.0192 | 0.0344 | Better | 28 | 0.224 [.08–0.65] |
Low SOCS3a + High RBL1 | Cell cycle | 0.0053 | 0.0123 | Poor | 23 | 2.20 [1.20–4.03] |
Low SOCS3a + High CXCL8 | RTK signalling, angiogenesis | 0.0017 | 0.0017 | Poor | 3 | 7.03 [1.70–28.99] |
Low SOCS3a + High FGFR1a | Proliferation | 0.0125 | 0.0173 | Poor | 4 | 4.15 [1.31–13.17] |
Low SOCS3a + Low DLEC1a | Proliferation | 0.0163 | 0.0324 | Poor | 22 | 2.01 [1.12–3.58] |
Low SOCS3a + High DAB2 | MAPK pathway | 0.0023 | 0.0023 | Poor | 10 | 3.42 [1.49–7.84] |
Low SOCS3a + High PIK3R1b | PI3K-AKT pathway | 0.0232 | 0.0232 | Better | 27 | 0.21 [0.07–0.6] |